ADC | Arginine decarboxylase | Enzymes
| | | | | Tissue enhanced |
ADCY2 | Adenylate cyclase 2 (brain) | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
ADCY5 | Adenylate cyclase 5 | Disease related genes Enzymes Potential drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
ADCYAP1 | Adenylate cyclase activating polypeptide 1 (pituitary) | Predicted secreted proteins
| | | | | Tissue enhanced |
ADCYAP1R1 | Adenylate cyclase activating polypeptide 1 (pituitary) receptor type I | G-protein coupled receptors Predicted membrane proteins Predicted secreted proteins Transporters
| | | | | Tissue enhanced |
ADIRF | Adipogenesis regulatory factor | Plasma proteins
| | | | | Tissue enhanced |
ADM2 | Adrenomedullin 2 | Predicted secreted proteins
| | | | | Tissue enhanced |
ADORA1 | Adenosine A1 receptor | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
ADORA2A | Adenosine A2a receptor | Cancer-related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
ADORA3 | Adenosine A3 receptor | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
ADRA1A | Adrenoceptor alpha 1A | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
ADRA1B | Adrenoceptor alpha 1B | Cancer-related genes FDA approved drug targets G-protein coupled receptors Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
ADRA1D | Adrenoceptor alpha 1D | FDA approved drug targets G-protein coupled receptors Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
ADRA2C | Adrenoceptor alpha 2C | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
ADRB1 | Adrenoceptor beta 1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
ADRB3 | Adrenoceptor beta 3 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
ADTRP | Androgen-dependent TFPI-regulating protein | Predicted membrane proteins
| | | | | Tissue enhanced |
AFAP1L2 | Actin filament associated protein 1-like 2 | | | | | | Tissue enhanced |
AFF2 | AF4/FMR2 family, member 2 | Disease related genes Plasma proteins
| | | | | Tissue enhanced |
AGAP2 | ArfGAP with GTPase domain, ankyrin repeat and PH domain 2 | | | | | | Tissue enhanced |
AGBL1 | ATP/GTP binding protein-like 1 | Disease related genes Enzymes Potential drug targets
| | | | | Tissue enhanced |
AGBL2 | ATP/GTP binding protein-like 2 | Enzymes
| | | | | Tissue enhanced |
AGBL4 | ATP/GTP binding protein-like 4 | Enzymes
| | | | | Tissue enhanced |
AGMAT | Agmatine ureohydrolase (agmatinase) | Enzymes Mitochondrial proteins
| | | | | Tissue enhanced |
AGMO | Alkylglycerol monooxygenase | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
AGR2 | Anterior gradient 2 | Predicted secreted proteins
| | | | | Tissue enhanced |
AGR3 | Anterior gradient 3 | Predicted secreted proteins
| | | | | Tissue enhanced |
AGRP | Agouti related protein homolog (mouse) | Disease related genes Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
AGT | Angiotensinogen (serpin peptidase inhibitor, clade A, member 8) | Candidate cardiovascular disease genes Disease related genes Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
AGTR1 | Angiotensin II receptor, type 1 | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
AIF1L | Allograft inflammatory factor 1-like | | | | | | Tissue enhanced |
AIM1L | Absent in melanoma 1-like | | | | | | Tissue enhanced |
AIM2 | Absent in melanoma 2 | | | | | | Tissue enhanced |
AIRE | Autoimmune regulator | Disease related genes Transcription factors
| | | | | Tissue enhanced |
AJAP1 | Adherens junctions associated protein 1 | Predicted membrane proteins
| | | | | Tissue enhanced |
AJUBA | Ajuba LIM protein | Cancer-related genes
| | | | | Tissue enhanced |
AK4 | Adenylate kinase 4 | Enzymes Mitochondrial proteins Predicted secreted proteins
| | | | | Tissue enhanced |
AK7 | Adenylate kinase 7 | Enzymes
| | | | | Tissue enhanced |
AK8 | Adenylate kinase 8 | Enzymes
| | | | | Tissue enhanced |
AKAP5 | A kinase (PRKA) anchor protein 5 | Plasma proteins
| | | | | Tissue enhanced |
AKAP6 | A kinase (PRKA) anchor protein 6 | Predicted membrane proteins
| | | | | Tissue enhanced |
AKNAD1 | AKNA domain containing 1 | | | | | | Tissue enhanced |
AKR1B10 | Aldo-keto reductase family 1, member B10 (aldose reductase) | | | | | | Tissue enhanced |
AKR1B15 | Aldo-keto reductase family 1, member B15 | | | | | | Tissue enhanced |
AKR1C2 | Aldo-keto reductase family 1, member C2 | Disease related genes Enzymes FDA approved drug targets
| | | | | Tissue enhanced |
AKR7A3 | Aldo-keto reductase family 7, member A3 (aflatoxin aldehyde reductase) | | | | | | Tissue enhanced |
AL031663.2 | CDNA FLJ26875 fis, clone PRS08969; Uncharacterized protein | | | | | | Tissue enhanced |
AL162407.1 | CDNA FLJ20147 fis, clone COL07954; HCG1781466; Uncharacterized protein | Predicted membrane proteins
| | | | | Tissue enhanced |
AL353354.2 | | Predicted secreted proteins
| | | | | Tissue enhanced |
AL353791.1 | | | | | | | Tissue enhanced |